Dr. Berd is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1652 Noble Circle
Jenkintown, PA 19046Phone+1 267-243-4987
Education & Training
Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 1972 - 1975
University of Pennsylvania Health SystemResidency, Internal Medicine, 1968 - 1970
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1968
Certifications & Licensure
PA State Medical License 1969 - 2024
GA State Medical License 1970 - 1977- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer Start of enrollment: 1999 Jul 01
- Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma Start of enrollment: 2005 Jun 01
Publications & Presentations
PubMed
- 51 citationsDouble-Blinded, Randomized Phase II Study Using Embolization with or without Granulocyte–Macrophage Colony-Stimulating Factor in Uveal Melanoma with Hepatic MetastasesMatias E. Valsecchi, Mizue Terai, David J. Eschelman, Carin F. Gonsalves, Inna Chervoneva
Journal of Vascular and Interventional Radiology. 2015-04-01 - 5 citationsA tale of two pities: autologous melanoma vaccines on the brink.David Berd
Human Vaccines & Immunotherapeutics. 2012-08-01 - 30 citationsInterleukin 6 mediates production of interleukin 10 in metastatic melanomaMizue Terai, Masumi Eto, Garbo D. Young, David Berd, Michael J. Mastrangelo
Cancer Immunology, Immunotherapy. 2012-02-01
Press Mentions
Clinical Study Collaborator HCL Sends First Surgically Excised Ovarian Cancer Tumors to BioVaxys for BVX-0918 Vaccine Process DevelopmentJune 15th, 2022- Research on a ‘Universal’ Sarbecovirus Vaccine Well UnderwayApril 26th, 2022
- BioVaxys Expands Cancer Vaccine PlatformMarch 30th, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
